Umbrajkar Sidhant, Stankowski Rachel V, Rezkalla Shereif, Kloner Robert A
University of California, Los Angeles (UCLA), 10833 Le Conte Ave., Los Angeles, CA 90095, USA.
Huntington Medical Research Institutes, 686 South Fair Oaks Ave., Pasadena, CA 91105, USA.
Cardiol Res. 2021 Apr;12(2):67-79. doi: 10.14740/cr1199. Epub 2021 Feb 23.
First documented in China in early December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread rapidly and continues to test the strength of healthcare systems and public health programs all over the world. Underlying cardiovascular disease has been recognized as a risk factor for coronavirus disease 2019 (COVID-19)-related morbidity and mortality since the early days of the pandemic. In addition, evidence demonstrates cardiac and endothelial damage in somewhere between one-third and three-quarters of individuals with COVID-19, regardless of symptom severity. This damage is thought to be mediated by direct viral infection, immunopathology and hypoxemia with the additional possibility of exacerbation via medication-induced cardiotoxicity. Clinically, the cardiovascular consequences of COVID-19 may present as myocarditis with or without arrhythmia, endothelial dysfunction and thrombosis, acute coronary syndromes and heart failure. Presentation can vary widely and may or may not be typical of the condition in an individual without COVID-19. There is evidence to support the prognostic utility of cardiac biomarkers (e.g., cardiac troponin) and imaging studies (e.g., echocardiography, cardiac magnetic resonance imaging) in the context of COVID-19 and building evidence suggests that cardiovascular screening may be warranted even among those with asymptomatic or mild infection and those without traditional cardiovascular risk factors. In addition, evidence suggests the potential for long-term cardiovascular consequences for those who recover from COVID-19 with implications for the field of cardiology long into the future. Even among those without COVID-19, disruption of infrastructure and changes in human behavior as a result of the pandemic also have an upstream role in cardiovascular outcomes, which have already been documented in multiple locations. This review summarizes what is currently known regarding the pathogenic mechanisms of COVID-19-related cardiovascular injury and describes clinical cardiovascular presentations, prognostic indicators, recommendations for screening and treatment, and long-term cardiovascular consequences of infection. Ultimately, medical personnel must be vigilant in their attention to possible cardiovascular symptoms, take appropriate steps for clinical diagnosis and be prepared for long-term ramifications of myocardial injury sustained as a result of COVID-19.
新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)于2019年12月初在中国首次被记录,迅速传播,持续考验着世界各地医疗系统和公共卫生项目的实力。自疫情初期以来,潜在心血管疾病就被认为是2019冠状病毒病(COVID-19)相关发病和死亡的一个危险因素。此外,有证据表明,无论症状严重程度如何,三分之一至四分之三的COVID-19患者存在心脏和内皮损伤。这种损伤被认为是由病毒直接感染、免疫病理学和低氧血症介导的,还可能因药物诱导的心脏毒性而加重。临床上,COVID-19的心血管后果可能表现为伴有或不伴有心律失常的心肌炎、内皮功能障碍和血栓形成、急性冠状动脉综合征和心力衰竭。表现形式可能差异很大,对于没有COVID-19的个体而言,可能是也可能不是该病的典型症状。有证据支持心脏生物标志物(如心肌肌钙蛋白)和影像学检查(如超声心动图、心脏磁共振成像)在COVID-19情况下的预后效用,越来越多的证据表明,即使在无症状或轻度感染的人群以及没有传统心血管危险因素的人群中,也可能有必要进行心血管筛查。此外,有证据表明,从COVID-19中康复的患者可能会出现长期心血管后果,这对心脏病学领域在很长一段时间内都有影响。即使在没有感染COVID-19的人群中,疫情导致的基础设施破坏和人类行为变化在心血管疾病结局方面也起着上游作用,多个地区已经记录了这一点。本综述总结了目前已知的COVID-19相关心血管损伤的致病机制,描述了临床心血管表现、预后指标、筛查和治疗建议以及感染后的长期心血管后果。最终,医务人员必须警惕可能出现的心血管症状,采取适当措施进行临床诊断,并为COVID-19导致的心肌损伤的长期后果做好准备。